Is aim Immunotech (AIM) stock a good buy?
According to 3 analysts, the average rating for AIM ImmunoTech stock is "Strong Buy." The 12-month stock price forecast is 6.88, which is an increase of 441.73% from the latest price.
Will Immunotech’s stock gain 3 days in a row?
The AIM ImmunoTech Inc. stock price gained 3.91% on the last trading day (Friday, 21st Jan 2022), rising from $0.82 to $0.85. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days.
Is aim Immunotech's P/E ratio undervalued?
The P/E ratio of AIM ImmunoTech is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. AIM ImmunoTech has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Where can I buy shares of aim?
Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is AIM stock a good buy?
The 3 analysts offering 12-month price forecasts for AIM ImmunoTech Inc have a median target of 6.50, with a high estimate of 7.50 and a low estimate of 3.00. The median estimate represents a +796.30% increase from the last price of 0.73.
Is Aim a yahoo?
(AIM) Stock Price, News, Quote & History - Yahoo Finance....Performance Outlook.Previous Close0.8100Bid0.7300 x 1400Ask0.7751 x 1300Day's Range0.7201 - 0.810052 Week Range0.5500 - 2.20003 more rows•Jul 22, 2022
How does the AIM market work?
Key Takeaways. The Alternative Investment Market (AIM) is a specialized unit of the London Stock Exchange (LSE) catering to smaller, more risky companies. The companies listed on AIM tend to be smaller and more highly speculative in nature, in part due to AIM's relaxed regulations and listing requirements.
How has AIM ImmunoTech's stock price performed in 2022?
AIM ImmunoTech's stock was trading at $0.92 at the beginning of 2022. Since then, AIM stock has decreased by 4.3% and is now trading at $0.88. Vie...
When is AIM ImmunoTech's next earnings date?
AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for AIM...
How were AIM ImmunoTech's earnings last quarter?
AIM ImmunoTech Inc. (NYSE:AIM) issued its quarterly earnings results on Monday, May, 16th. The company reported ($0.08) earnings per share for the...
Who are AIM ImmunoTech's key executives?
AIM ImmunoTech's management team includes the following people: Mr. Thomas K. Equels Esq. , J.D., M.S., Exec. Vice Chairman, CEO & Pres (Age 69,...
Who are some of AIM ImmunoTech's key competitors?
Some companies that are related to AIM ImmunoTech include Armata Pharmaceuticals (ARMP) , Gritstone bio (GRTS) , Fusion Pharmaceuticals (FUSN) ,...
What other stocks do shareholders of AIM ImmunoTech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceutical...
What is AIM ImmunoTech's stock symbol?
AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."
Who are AIM ImmunoTech's major shareholders?
AIM ImmunoTech's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.27...
Which major investors are selling AIM ImmunoTech stock?
AIM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors L...
When will AIM ImmunoTech release its earnings?
What is the P/E ratio of AIM Immunotech?
AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021. View our earnings forecast for AIM ImmunoTech.
Where does AIM trade?
The P/E ratio of AIM ImmunoTech is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is AIM ImmunoTech a buy?
AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."
Does AIM Immunotech pay dividends?
AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Who is the CEO of AIM Immunotech?
AIM ImmunoTech does not currently pay a dividend.
When is the AIM conference call 2021?
AIM ImmunoTech CEO says the firm in ‘solid financial standing' to move forward rapidly with clinical programs. AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Thomas Equels told investors that the immuno-pharma company rounded out the first quarter by increasing its cash reserves to “aggressively move forward” with it...
What country has a patent for ampligen?
AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones AIM to host investor...
Is AIM Immunotech approved?
The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for U...
What is AIM Immunotech?
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) said it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of its drug Ampligen as an...
Where is AIM Immunotech located?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company’s products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
What is AIM Immunotech?
and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
What is market cap?
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, col
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
Signals & Forecast
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 6.75%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is AIM ImmunoTech Inc. stock A Buy?
AIM ImmunoTech Inc. finds support from accumulated volume at $0.78 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very negative
AIM ImmunoTech Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 1 trades there were . The last trade was done 19 046 days ago by who bough 0 shares.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!